Oxycodone extended release capsules for the treatment of chronic pain

References

• Ashworth J, Green D, Dunn K, et al. Opioid use among low back pain patients in primary care: is opioid prescription associated with disability at 6-month follow-up? Pain. 2013;154:1038–1044.
   PubMed Web of Science ®Google Scholar
• Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain. 2012;13:715–724.
   PubMed Web of Science ®Google Scholar
• Mercadante S. The use of opioids for treatment of cancer pain. Expert Opin Pharmacother. 2015;16:389–394.
   PubMed Web of Science ®Google Scholar
• Cheung CW, Qiu Q, Choi SW, et al. Chronic opioid therapy for chronic non-cancer pain: A review and comparison of treatment guidelines. Pain Physician. 2014;17:401–414.
   PubMed Web of Science ®Google Scholar
• Franklin GM. Opioids for chronic noncancer pain: A position paper of the American academy of neurology. Neurology. 2014;83:1277–1284.
   PubMed Web of Science ®Google Scholar
• McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther. 2001;8:181–186.
   PubMedGoogle Scholar
• Nicholson B. Benefits of extended-release opioid analgesic formulations in the treatment of chronic pain. Pain Pract. 2009;9:71–81.
   PubMed Web of Science ®Google Scholar
• Comer SD, Ashworth JB, Sullivan MA, et al. Relationship between rate of infusion and reinforcing strength of oxycodone in humans. J Opioid Manag. 2009;5:203–212.
   PubMedGoogle Scholar
• Mercadante S, Craig D, Giarratano A. US food and drug administration’s risk evaluation and mitigation strategy for extended-release and long-acting opioids: pros and cons, and a European perspective. Drugs. 2012;72:2327–2332.
   PubMed Web of Science ®Google Scholar
• Bannwarth B. Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose? Drugs. 2012;72:1713–1723.
   PubMed Web of Science ®Google Scholar
• Birnbaum H, White A, Schiller M, et al. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12:657–667.
   PubMed Web of Science ®Google Scholar
• Breitbart W, Passik S, McDonald M, et al. Patient-related barriers to pain management in ambulatory AIDS patients. Pain. 1998;76:9–16.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration, National Survey on Drug Use and Health: Summary of National Findings (NSDUH). 2002–2013. Past Month Illicit Drug Use among Persons Aged 12 or Older. 2014.
   Google Scholar
• Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network, 2011: National estimates of drug-related emergency department visits. HHS Publication No. (SMA) 13-4760, DAWN Series D-39. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013.
   Google Scholar
• Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372:241–248.
   PubMed Web of Science ®Google Scholar
• Larochelle MR, Zhang F, Ross-Degnan D, et al. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene. JAMA Intern Med. 2015;2015(175):978–987.
   Web of Science ®Google Scholar
• Raffa RB, Pergolizzi JV Jr. Opioid formulations designed to resist/deter abuse. Drugs. 2010;70:1657–1675.
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr, Taylor R Jr, Nalamachu S, et al. Challenges of treating patients with chronic pain with dysphagia (CPD): physician and patient perspectives. Curr Med Res Opin. 2014;30:191–202.
   PubMed Web of Science ®Google Scholar
• Fleming AB, Scungio TA, Grima MP, et al. In vitro assessment of the potential for abuse via the intravenous route of oxycodone DETERx® microspheres. J Opioid Manag. 2016;12:57–65.
   PubMedGoogle Scholar
• Katz N, Kopecky EA, OʼConnor M, et al. A phase 3, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER in patients with moderate-to-severe chronic low back pain. Pain. 2015;156:2458–2467.
   PubMed Web of Science ®Google Scholar
• Nalamachu S, Kopecky EA, Taylor R Jr, et al. Evaluation of the durability of pain relief throughout a 12 hour dosing interval of a novel, extended-release, abuse-deterrent formulation of oxycodone. Curr Med Res Opin. 2016;32:1311–1317.
   PubMed Web of Science ®Google Scholar
• Gudin J, Levy-Cooperman N, Kopecky EA, et al. Comparing the effect of tampering on the oral pharmacokinetic profiles of two extended-release oxycodone formulations with abuse-deterrent properties. Pain Med. 2015;16:2142–2151. .
   PubMed Web of Science ®Google Scholar
• Kopecky EA, Fleming AB, Noonan PK, et al. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation. J Opioid Manag. 2014;10:233–246.
   PubMedGoogle Scholar
• Kopecky EA, Fleming AB, Levy-Cooperman N, et al. Oral human abuse potential of oxycodone DETERx® (Xtampza® ER). J Clin Pharmacol. 2016 Sep 27. [Epub ahead of print]. DOI:10.1002/jcph.833
   PubMedGoogle Scholar
• Webster LR, Kopecky EA, Smith MD, et al. A randomized, double-blind, double-dummy study to evaluate the intranasal human abuse potential and pharmacokinetics of a novel extended-release abuse-deterrent formulation of oxycodone. Pain Med. 2016;17:1112–1130. .
   PubMed Web of Science ®Google Scholar
• McCarberg BH, Ernest A, Kopecky EA, et al. An abuse-deterrent, microsphere-in-capsule formulation of extended-release oxycodone: alternative modes of administration to facilitate pain management in patients with dysphagia. Curr Med Res Opin. 2016;32:1975–1982.
   PubMed Web of Science ®Google Scholar